Thrivent Financial for Lutherans’s Amneal Pharmaceuticals AMRX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Sell	113,125 -182	-0.2%	-$2.49K	﹤0.01%	1565
2026 Q1	$1.41M	Buy	113,307 +58,698	+107%	+$788K	﹤0.01%	1680
2025 Q4	$688K	Sell	54,609 -38,075	-41%	-$436K	﹤0.01%	2130
2025 Q3	$927K	Buy	92,684 +35,076	+61%	+$315K	﹤0.01%	1817
2025 Q2	$466K	Hold	57,608	–	–	﹤0.01%	2172
2025 Q1	$483K	Buy	+57,608	New	+$481K	﹤0.01%	2088
2024 Q3	–	Sell	-94,839	Closed	-$602K	–	2510
2024 Q2	$602K	Sell	94,839 -4,050	-4%	-$25.7K	﹤0.01%	2142
2024 Q1	$599K	Hold	98,889	–	–	﹤0.01%	2160
2023 Q4	$600K	Buy	+98,889	New	+$440K	﹤0.01%	2141
2022 Q3	–	Sell	-51,282	Closed	-$164K	–	2403
2022 Q2	$164K	Buy	+51,282	New	+$186K	﹤0.01%	2373

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Thrivent Financial for Lutherans's AMRX Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its Amneal Pharmaceuticals (AMRX) stake by 0.16% in Q2 2026, selling an estimated $2.49K and leaving 113,125 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1565.

Thrivent Financial for Lutherans first reported a position in AMRX in Q2 2022 and has held it in 10 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Thrivent Financial for Lutherans held 113,125 shares of Amneal Pharmaceuticals worth $1.96M as of Q2 2026.
Thrivent Financial for Lutherans sold 182 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.49K.
Amneal Pharmaceuticals made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1565 holding.
Thrivent Financial for Lutherans first reported a position in Amneal Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.